SML2052

LCAT activator compound A

≥98% (HPLC)

• Synonym(e): 3-[[5-(Ethylthio)-1,3,4-thiadiazol-2-yl]thio]-2-pyrazinecarbonitrile, 3-[[5-(Ethylthio)-1,3,4-thiadiazol-2-yl]thio]pyrazine-2-carbonitrile, Compound A
• Empirische Formel (Hill-System): C₉H₇N₅S₃
• CAS-Nummer: 1000269-30-6
• Molekulargewicht: 281.38
• UNSPSC Code: 41106609
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• assay: ≥98% (HPLC)
• form: powder
• color: white to brown
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: −20°C
• SMILES string: CCSC1=NN=C(S1)SC2=NC=CN=C2C#N
• InChI: 1S/C9H7N5S3/c1-2-15-8-13-14-9(17-8)16-7-6(5-10)11-3-4-12-7/h3-4H,2H2,1H3
• InChI key: UBSFSJMIJHSGDZ-UHFFFAOYSA-N

Beschreibung

Biochem/physiol Actions

LCAT activator compound A is an activator of Lecithin:cholesterol acyltransferase (LCAT) including some mutant LCATs found in Familial LCAT Deficiency (FLD). LCAT activator compound A forms a covalent hydrophobic adduct with LCAT Cys 31. The chronic treatment with LCAT activator compound A results in a significant increase in HDLc, HDL particle, size, plasma apolipoprotein A-I level, plasma cholesteryl ester to free cholesterol ratio, and a significant reduction in very low-density lipoprotein cholesterol in hamsters.

Lecithin:cholesterol acyltransferase (LCAT) including some FLD mutant LCATs

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable